- Email: [email protected]
Recognition and prevalence of non motor symptoms of Parkinson’s disease and their awareness; study using non motor symptoms questionnaire in 50 patients
226
Abstracts / Journal of the Neurological Sciences 405S (2019) 116542
Conclusion Although no muscle strengthening effect was found in skeletal muscle, respiratory function was improved. The disappearance of waning after treatment suggested that nusinersen improves the function of the neuromuscular junction.
Keywords: Parkinson’s questionnaire
disease,
Motor
Symptoms,
NMS
doi:10.1016/j.jns.2019.10.1226
doi:10.1016/j.jns.2019.10.1225
WCN19-0715 WCN19-0705 Journal of the Neurological Sciences 405S (2019) 104888
Journal of the Neurological Sciences 405S (2019) 104889 Poster Session 3
Poster Session 3
Increased serum and CSF levels of S100B reflect glial cells degeneration in PD
Recognition and prevalence of non motor symptoms of Parkinson’s disease and their awareness; study using non motor symptoms questionnaire in 50 patients
E. Papuć, K. Rejdak Medical University of Lublin, Department of Neurology, Lublin, Poland
N. Yaqoob, A. Herekar Baqai Medical University, Neurology, Karachi, Pakistan Objective The aim of this study was to explore the prevalence of non motor symptoms of Parkinson’s disease and the patient’s awareness of these symptoms by using Non Motor Symptoms, (NMS) screening questionnaire consisting of 30 items. Place and duration of study Baqai Medical University, Karachi, Pakistan from March 2017 to January 2018. Patients & methods 50 patients were evaluated using the definitive version of Non Motor Symptoms (NMS) questionnaire, in the Out Patient Department (OPD), highlighting the frequency of non motor symptoms in males and females patients of Parkinson’s disease. Results All 50 patients had more than one symptom. Symptoms encountered in patients were feeling anxious and frightened 42 (84%), feeling sad, low and blue 39 (78%), unpleasant sensation in legs 35 (70%), unexplained pains 35 (70%), feeling light headed and dizzy 33 (66%), sense of urgency to pass urine 31 (62%), unexplained change in weight 28 (56%), difficulty getting to sleep 26 (52%), dribbling saliva 22 (44%), difficulty concentrating 20 (40%), constipation 30 (60%), problem remembering things 30 (60%). Feeling anxious and frightened was the most common symptom in males (84%) and feeling sad, low and blue in females (100%). 46 patients were unaware of any relationship between Parkinson’s disease and these non motor Symptoms. Conclusion For Parkinson’s disease to be properly managed, non motor symptoms should be comprehensively assessed and addressed to ensure that the patients are informed about their association with Parkinson’s disease.
Introduction There is increasing evidence that glial cells degeneration is involved in the initiation and progression of PD in addition to neural structures. S100B is a calcium binding protein, mainly expressed and produced in astrocytes. It has been shown that S100B is only expressed by a subtype of mature astrocytes that ensheath blood vessels. S100B is also a candidate peripheral biomarker of blood– brain barrier (BBB) permeability. Methods Subjects were 28 patients with PD and 28 healthy controls. All PD and control subjects underwent S100B assessment in serum and csf. Both groups were matched for gender but not for age (PD 65.18 ± 8,64 vs controls 48.14 ± 13.71 years; p N 0.05). S100B levels in serum and csf were assessed using commercially available ELISA kit. Results We found statistically significant differences in serum levels of S100B protein between PD and healthy controls groups (24,65 ± 11.94 vs 14,47 ± 7,24 pg/ml; p b 0.05). Csf levels of S100B protein in PD patients were also significantly higher than in healthy controls (133,52 ± 54.72 vs 114,86 ± 120.69 pg/ml; p b 0.05). No correlation was found between serum and csf levels of S100B among healthy control subjects. Statistically significant positive correlation was found between serum and csf levels of S100B among PD patients (p = 0.003). Conclusions Results of our study confirm glial cells damage in PD. Additionally, a positive correalation between csf and serum levels of S100B among parkinsonian patients, confirm BBB damage in PD and suport the concept of S100B being a biomarker of BBB permeability. doi:10.1016/j.jns.2019.10.1227
Abstracts / Journal of the Neurological Sciences 405S (2019) 116542
Conclusion Although no muscle strengthening effect was found in skeletal muscle, respiratory function was improved. The disappearance of waning after treatment suggested that nusinersen improves the function of the neuromuscular junction.
Keywords: Parkinson’s questionnaire
disease,
Motor
Symptoms,
NMS
doi:10.1016/j.jns.2019.10.1226
doi:10.1016/j.jns.2019.10.1225
WCN19-0715 WCN19-0705 Journal of the Neurological Sciences 405S (2019) 104888
Journal of the Neurological Sciences 405S (2019) 104889 Poster Session 3
Poster Session 3
Increased serum and CSF levels of S100B reflect glial cells degeneration in PD
Recognition and prevalence of non motor symptoms of Parkinson’s disease and their awareness; study using non motor symptoms questionnaire in 50 patients
E. Papuć, K. Rejdak Medical University of Lublin, Department of Neurology, Lublin, Poland
N. Yaqoob, A. Herekar Baqai Medical University, Neurology, Karachi, Pakistan Objective The aim of this study was to explore the prevalence of non motor symptoms of Parkinson’s disease and the patient’s awareness of these symptoms by using Non Motor Symptoms, (NMS) screening questionnaire consisting of 30 items. Place and duration of study Baqai Medical University, Karachi, Pakistan from March 2017 to January 2018. Patients & methods 50 patients were evaluated using the definitive version of Non Motor Symptoms (NMS) questionnaire, in the Out Patient Department (OPD), highlighting the frequency of non motor symptoms in males and females patients of Parkinson’s disease. Results All 50 patients had more than one symptom. Symptoms encountered in patients were feeling anxious and frightened 42 (84%), feeling sad, low and blue 39 (78%), unpleasant sensation in legs 35 (70%), unexplained pains 35 (70%), feeling light headed and dizzy 33 (66%), sense of urgency to pass urine 31 (62%), unexplained change in weight 28 (56%), difficulty getting to sleep 26 (52%), dribbling saliva 22 (44%), difficulty concentrating 20 (40%), constipation 30 (60%), problem remembering things 30 (60%). Feeling anxious and frightened was the most common symptom in males (84%) and feeling sad, low and blue in females (100%). 46 patients were unaware of any relationship between Parkinson’s disease and these non motor Symptoms. Conclusion For Parkinson’s disease to be properly managed, non motor symptoms should be comprehensively assessed and addressed to ensure that the patients are informed about their association with Parkinson’s disease.
Introduction There is increasing evidence that glial cells degeneration is involved in the initiation and progression of PD in addition to neural structures. S100B is a calcium binding protein, mainly expressed and produced in astrocytes. It has been shown that S100B is only expressed by a subtype of mature astrocytes that ensheath blood vessels. S100B is also a candidate peripheral biomarker of blood– brain barrier (BBB) permeability. Methods Subjects were 28 patients with PD and 28 healthy controls. All PD and control subjects underwent S100B assessment in serum and csf. Both groups were matched for gender but not for age (PD 65.18 ± 8,64 vs controls 48.14 ± 13.71 years; p N 0.05). S100B levels in serum and csf were assessed using commercially available ELISA kit. Results We found statistically significant differences in serum levels of S100B protein between PD and healthy controls groups (24,65 ± 11.94 vs 14,47 ± 7,24 pg/ml; p b 0.05). Csf levels of S100B protein in PD patients were also significantly higher than in healthy controls (133,52 ± 54.72 vs 114,86 ± 120.69 pg/ml; p b 0.05). No correlation was found between serum and csf levels of S100B among healthy control subjects. Statistically significant positive correlation was found between serum and csf levels of S100B among PD patients (p = 0.003). Conclusions Results of our study confirm glial cells damage in PD. Additionally, a positive correalation between csf and serum levels of S100B among parkinsonian patients, confirm BBB damage in PD and suport the concept of S100B being a biomarker of BBB permeability. doi:10.1016/j.jns.2019.10.1227